<DOC>
	<DOCNO>NCT01119339</DOCNO>
	<brief_summary>The aim study intra-individually compare dose-related efficacy LAS41004 Psoriasis Plaque Test ( PPT )</brief_summary>
	<brief_title>Study Investigate Dose-related Efficacy LAS41004 Treatment Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Male female patient 18 75 year age diagnosis stable plaquetype psoriasis ( psoriasis vulgaris ) least 6 month Psoriasis plaques suitable defined target area lesion follow criterion : 1 . Psoriasis plaque must locate trunk and/or extremity . Plaques locate head ( incl . scalp ) , palm , sole foot , intertriginous genitoanal area suitable target area 2 . Comparable psoriasis plaque least `` 2 '' score ( Range 04 ) three distinct symptom scale ; erythema ; induration 3 . No 3 point difference total score ( = sum score scale , erythema induration ; Range 012 ) choose comparable psoriasis plaque 4 . Enough psoriatic surface area define 8 clearly distinguishable ( minimum distance test area : 1cm ) test area least 1 cmÂ² plaque size Patient willing able comply requirement clinical study protocol . In particular , patient must adhere concomitant therapy prohibition test area must agree avoid intense UV exposure test area study Written inform consent participate study , prior study related procedure , indicate understand purpose study A patient childbearing potential agrees use one follow contraceptive method duration study : 1 . Strict abstinence ( exception : male partner vasectomy least 3 month prior study entry allow ) 2 . Combined oral , implanted injectable contraceptive stable dose least 3 month prior study entrance 3 . Intrauterine device ( IUD ) insert least 1 month prior study entrance Too body surface area cover psoriasis plaque meet specified inclusion criterion define 8 clearly distinguishable test area Any condition may interfere study assessment sonographic measurement skin and/or may influence skin immune response ( incl . open wound ) Known adverse reaction severity hypersensitivity ingredient test product No willingness avoid induction heavy sweating , e.g . due sauna visit , excessive sport activity study course No willingness avoid swimming , bath wet designate test area visit Pregnant breastfeed woman A medical condition may put patient general risk therefore would prevent participation clinical trial ( include limit : serious infectious disease , major surgery within last 4 week , coronary artery disease , renal impairment , hepatic impairment , uncontrolled metabolic disease , disorder calcium metabolism , autoimmune disease ) History presence malignant disease ( surgically remove basal cell carcinoma ) and/or auto immune disease Current diagnosis guttate , erythrodermic pustular psoriasis Patients respect follow washout period prior study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>psoriasis</keyword>
	<keyword>topical</keyword>
	<keyword>psoriasis plaque test</keyword>
</DOC>